ClareJTwistMD

Pediatric Hematology & Oncology • Buffalo, NY

Pediatric Solid Tumor Oncology

Clinical Professor and Fellowship Program Director, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo; Professor, Roswell Park Comprehensive Cancer Center; Director of Pediatric Experimental Therapeutics, Roswell Park Comprehensive Cancer Center

Join to view full profile

Dr. Twist is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Twist's full profile

Already have an account?

Office
Elm and Carlton St
Buffalo, NY 14263
Phone+1 716-845-2300

Fax+1 716-845-8003

Education & Training

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1990 - 1993
McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 1988 - 1990
McGaw Medical Center of Northwestern UniversityInternship, Pediatrics, 1987 - 1988
Albany Medical CollegeClass of 1987

Certifications & Licensure

CA State Medical License 1999 - Present
NY State Medical License 2016 - 2026
IL State Medical License 1987 - 1990
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Outstanding Resident Teacher Award Children's Memorial Hospital, 1990

Clinical Trials

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
Completed
Phase 1
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Start of enrollment: 2007 Oct 08
Completed
Phase 3
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma Start of enrollment: 2006 Dec 01
Completed
Phase 1
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01
Completed
Phase 1
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01
Completed
Phase 1
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma Start of enrollment: 2010 Dec 01
Completed
Phase 1
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04
Active, not recruiting
Phase 1
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 1
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 2
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma Start of enrollment: 2022 Jul 01
Recruiting
Phase 1
Roles: Study Chair, Contact
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura Start of enrollment: 2021 Apr 14
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology...
Julie Voeller, Howard M Katzenstein, Arlene Naranjo, Sheena C Tenney, Lulu Chen
Pediatric Blood & Cancer. 2025-01-01
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Erin G Brown, E Stanton Adkins, Peter Mattei, Fredric A Hoffer, Sandra L Wootton-Gorges
Journal of Pediatric Surgery. 2024-09-06
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group stud...
Erin K Barr, Arlene Naranjo, Clare J Twist, Sheena C Tenney, Mary Lou Schmidt
Pediatric Blood & Cancer. 2024-08-01

Press Mentions

Roswell Park-Developed Immunotherapy Now Part of Nationwide Study in Kids with Brain CancerJune 7th, 2022

Professional Memberships

Children's Oncology Group
Member
American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member
American Society of Pediatric Hematology/Oncology
Member

External Links

Roswell Park Comprehensive Cancer Centerhttps://www.roswellpark.org/
Oishei Children's Hospitalhttp://ochbuffalo.org
University at Buffalo Department of Pediatricshttp://medicine.buffalo.edu/pediatrics